These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37159131)

  • 1. Serum biomarkers for monitoring response to tuberculosis treatment: an assessment of the effect of different covariates among slow and fast treatment responders.
    Namuganga AR; Ssentalo Bagaya B; Chegou NN; Mayanja-Kizza H
    Biomarkers; 2023 Dec; 28(5):466-476. PubMed ID: 37159131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of host protein biomarkers among symptomatic clinic attendees finally diagnosed with tuberculosis and other respiratory diseases with or without latent Mycobacterium tuberculosis infection.
    Namuganga AR; Nsereko M; Bagaya BS; Mayanja-Kizza H; Chegou NN
    Immunol Lett; 2023 Jan; 253():8-18. PubMed ID: 36463987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Host Cytokine Patterns of TB Patients with Different Bacterial Loads Detected Using 16S rRNA Analysis.
    Heslop R; Bojang AL; Jarju S; Mendy J; Mulwa S; Secka O; Mendy FS; Owolabi O; Kampmann B; Sutherland JS
    PLoS One; 2016; 11(12):e0168272. PubMed ID: 27992487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.
    Namugenyi J; Musaazi J; Katamba A; Kalyango J; Sendaula E; Kambugu A; Fehr J; Castelnouvo B; Manabe YC; Ssengooba W; Sekaggya-Wiltshire C
    BMC Infect Dis; 2021 Jun; 21(1):513. PubMed ID: 34074248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of blood C-reactive protein concentration complements the resolution of sputum bacillary load in patients on anti-tuberculosis therapy.
    Azam K; Khosa C; Viegas S; Massango I; Bhatt N; Jani I; Heinrich N; Hoelscher M; Gillespie SH; Rachow A; Sabiiti W
    Front Immunol; 2022; 13():1005692. PubMed ID: 36189292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment.
    Jacobs R; Tshehla E; Malherbe S; Kriel M; Loxton AG; Stanley K; van der Spuy G; Walzl G; Chegou NN
    Cytokine; 2016 May; 81():50-6. PubMed ID: 26878648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Vitamin D levels in correlation with circulatory proteins could be a potential biomarker tool for pulmonary tuberculosis and treatment monitoring.
    Moideen K; Nathella PK; Madabushi S; Renji RM; Srinivasan P; Ahamed SF; Rajkumar H; Bethunaickan R; Babu S
    Cytokine; 2023 Aug; 168():156238. PubMed ID: 37276815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.
    Kedia K; Wendler JP; Baker ES; Burnum-Johnson KE; Jarsberg LG; Stratton KG; Wright AT; Piehowski PD; Gritsenko MA; Lewinsohn DM; Sigal GB; Weiner MH; Smith RD; Jacobs JM; Nahid P
    Tuberculosis (Edinb); 2018 Sep; 112():52-61. PubMed ID: 30205969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    Kawasaki M; Echiverri C; Raymond L; Cadena E; Reside E; Gler MT; Oda T; Ito R; Higashiyama R; Katsuragi K; Liu Y
    PLoS Med; 2019 Apr; 16(4):e1002780. PubMed ID: 30978194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda.
    Nakiyingi L; Bwanika JM; Kirenga B; Nakanjako D; Katabira C; Lubega G; Sempa J; Nyesiga B; Albert H; Manabe YC
    PLoS One; 2013; 8(9):e74023. PubMed ID: 24040151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.
    Goodridge A; Cueva C; Lahiff M; Muzanye G; Johnson JL; Nahid P; Riley LW
    Tuberculosis (Edinb); 2012 May; 92(3):243-7. PubMed ID: 22406155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of serum bradykinin and desArg
    Qian X; Nguyen DTM; Li Y; Lyu J; Graviss EA; Hu TY
    Tuberculosis (Edinb); 2016 Dec; 101S():S109-S118. PubMed ID: 27720377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of delayed culture conversion among Ugandan patients.
    Atwine D; Orikiriza P; Taremwa I; Ayebare A; Logoose S; Mwanga-Amumpaire J; Jindani A; Bonnet M
    BMC Infect Dis; 2017 Apr; 17(1):299. PubMed ID: 28438118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment.
    Ndiaye MDB; Ranaivomanana P; Rasoloharimanana LT; Rasolofo V; Ratovoson R; Herindrainy P; Rakotonirina J; Schoenhals M; Hoffmann J; Rakotosamimanana N
    Sci Rep; 2022 Nov; 12(1):20640. PubMed ID: 36450921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Circulating CD4
    Ferrian S; Ross M; Conradie F; Vally Omar S; Ismail N; Little F; Kaplan G; Fallows D; Gray CM
    Front Immunol; 2018; 9():2438. PubMed ID: 30410488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.
    Jayakumar A; Vittinghoff E; Segal MR; MacKenzie WR; Johnson JL; Gitta P; Saukkonen J; Anderson J; Weiner M; Engle M; Yoon C; Kato-Maeda M; Nahid P;
    Tuberculosis (Edinb); 2015 Jul; 95(4):415-20. PubMed ID: 26022314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum inflammatory profiles in pulmonary tuberculosis and their association with treatment response.
    Choi R; Kim K; Kim MJ; Kim SY; Kwon OJ; Jeon K; Park HY; Jeong BH; Shin SJ; Koh WJ; Lee SY
    J Proteomics; 2016 Oct; 149():23-30. PubMed ID: 27321581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serodiagnostic markers for the prediction of the outcome of intensive phase tuberculosis therapy.
    Baumann R; Kaempfer S; Chegou NN; Nene NF; Veenstra H; Spallek R; Bolliger CT; Lukey PT; van Helden PD; Singh M; Walzl G
    Tuberculosis (Edinb); 2013 Mar; 93(2):239-45. PubMed ID: 23127778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.
    Nahid P; Bliven-Sizemore E; Jarlsberg LG; De Groote MA; Johnson JL; Muzanyi G; Engle M; Weiner M; Janjic N; Sterling DG; Ochsner UA
    Tuberculosis (Edinb); 2014 May; 94(3):187-96. PubMed ID: 24629635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis?
    Sivakumaran D; Jenum S; Ritz C; Vaz M; Doherty TM; Grewal HMS
    Front Immunol; 2022; 13():801616. PubMed ID: 35401549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.